Medical Gas Market Forecast and Company Analysis Report 2025-2033 Featuring Air Liquide, Linde, Atlas Copco, Inox-Air, Taiyo Nippon Sanso, Matheson Tri-Gas, Horiba, Sol
Medical Gas Market
Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Medical Gas Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The Global Medical Gas Market is expected to reach US$ 28.61 billion by 2033 from US$ 14.41 billion in 2024, with a CAGR of 7.92% from 2025 to 2033. Some of the key reasons driving the market are the growing tendency toward home healthcare and telemedicine, the prevalence of chronic illnesses including respiratory and cardiovascular diseases (CVDs), and many developments in medical technology.
The aging population, rising rates of chronic respiratory conditions, and improvements in healthcare infrastructure are all contributing to the substantial expansion of the worldwide medical gas market. Medical gases, such as carbon dioxide, nitrous oxide, and oxygen, are necessary for a number of therapeutic and diagnostic uses in ambulatory surgery centers, home healthcare settings, and hospitals. The need for portable medical gas solutions, such oxygen concentrators, has increased due to the growing demand for home healthcare services.
Due to growing healthcare sectors and government expenditures in medical infrastructure, the Asia-Pacific region is expected to develop at the highest rate, while North America already has a significant market share. The availability and distribution of medical gases may be impacted by supply chain interruptions and strict regulatory restrictions, which provide difficulties for the sector.The need for medicinal gases is also being fueled by the increasing incidence of asthma. The Australian Institute of Health and Welfare (AIHW) estimates that in 2023, asthma accounted for 35% of the entire burden related to all respiratory disorders and 2.5% of the overall illness burden. Nitrous oxide, carbon dioxide, nitrogen, oxygen, and medical air are some of the most often utilized medical gases in hospitals.One of the leading companies, Air Liquide Healthcare, provides medicinal gases to 20,000 hospitals and new healthcare facilities, and assists over 2 million people in managing chronic illnesses. Medical gases including heliox, oxygen, and lung gas mixes are widely employed in the diagnosis and treatment of certain respiratory conditions.Additionally, the need for portable medical gases, such as oxygen concentrators, is rising as more people choose home-based healthcare. In order to ensure that chronic patients receive the oxygen therapy they require at home, this change places an emphasis on convenience and continuity of care. Home healthcare has become increasingly popular in recent years and is predicted to continue to grow. Many medical illnesses may now be successfully treated at home, including those that require ventilator assistance, mixed gas therapies, and long-term oxygen therapy.
Additionally, it is anticipated that rising home healthcare reimbursement would support market expansion throughout the projection period. The Firesafe Cannula Valve, for example, was formally covered by Iowa Medicaid in November 2023 and was given the HCPCS number E0700 for reimbursement. In the event that the oxygen tubing downstream burns, this novel mechanism functions as a thermal fuse and instantly stops the oxygen supply. Thermal fuses must be installed in all home oxygen systems in the United Kingdom. Interestingly, the US has a 20-fold greater risk of death from oxygen-related flames than England, where installing firebreaks has been required since 2006.Growth Drivers for the Medical Gas Market
Numerous Medical Technology AdvancementsLaparoscopy and endoscopy are examples of minimally invasive (MI) surgical techniques that have been made possible by technological breakthroughs. Surgeons can execute treatments with fewer incisions, quicker patient recovery, and less tissue stress when medical gases like carbon dioxide are utilized to provide a clean operating field. Furthermore, more specialized and individualized treatment for respiratory problems is now possible because to developments in respiratory therapy equipment.
The World Health Organization reports that asthma and other chronic respiratory diseases (CRDs) are on the rise worldwide, with 3.2 million deaths from COPD and 262 million cases of asthma in 2019. Advanced oxygen treatment equipment, such as portable oxygen delivery systems and oxygen concentrators, are used to supply medical gases like oxygen. Additionally, a number of developments in dermatology and cryosurgery have increased the use of medicinal gases, such as liquid nitrogen, to freeze and remove sick or aberrant tissue. The market is being driven by the regulated and focused treatment that cryotherapy equipment provides, which minimizes harm to nearby healthy tissue.Growing Preference for Telemedicine and Home HealthcareMedical gases, such as oxygen, are frequently given to patients in their homes as part of home healthcare. To control their symptoms and enhance their quality of life, patients with long-term respiratory diseases like COPD need oxygen treatment. Medical oxygen gases are in greater demand as a result of the shift toward home healthcare, which enables patients to obtain oxygen therapy without the need for extended hospital stays. Furthermore, nebulization, pain relief, and respiratory therapies are only a few of the uses for medical gases that go beyond oxygen therapy. As a result of this trend, fewer extended hospital stays are required, which raises the requirement for medical oxygen.Additionally, as cardiovascular disorders are thought to cause 17.9 million deaths worldwide each year, medicinal gases - such as oxygen - are essential for treating associated ailments, which raises the need for at-home therapies. The need for medical gases is further increased by the growth of telemedicine and home healthcare, which enables patients to receive a greater variety of medical gas treatments in the convenience of their own homes.Rising Rates of Chronic Conditions, Including Heart and Respiratory ConditionsMedical gases like oxygen are necessary for respiratory support because to the rising prevalence of respiratory conditions such asthma, interstitial lung disorders, and chronic obstructive pulmonary disease (COPD). Chronic respiratory disorders (CRDs), such as asthma, interstitial lung diseases, and chronic obstructive pulmonary disease (COPD), are on the rise, according to the World Health Organization (WHO). According to the Global Asthma Report, asthma affects an estimated 262 million people globally, and COPD alone was responsible for almost 3.2 million deaths in 2019.Oxygen treatment is necessary for patients who have trouble breathing in order to keep their blood oxygen levels sufficient and to relieve their symptoms. Furthermore, medicinal gases are frequently needed for diagnostic and therapeutic purposes in cardiovascular illnesses, such as heart failure, coronary artery disease, and hypertension. In order to ensure patient comfort and stability during cardiovascular procedures, nitrous oxide is used as an anesthetic agent. Additionally, medicinal gases are essential for palliative care for individuals with chronic illnesses that have progressed.Challenges in the Medical Gas Market
Stringent Regulatory ComplianceBecause medical gases are essential to patient care and safety, the market is subject to strict regulatory compliance. To guarantee that medical gases fulfill therapeutic needs, regulatory agencies impose stringent criteria for purity, labeling, packing, and transportation. Operational complexity can be further increased by the constant monitoring, certification procedures, and thorough paperwork that are frequently required to comply with these rules. To maintain compliance, manufacturers must spend more on qualified staff and sophisticated quality control systems, which raises prices. Furthermore, managing disparate regional restrictions might make international distribution plans more difficult. Although these regulations guarantee patient safety and product dependability, they also place a financial and logistical strain on manufacturers, particularly newly established smaller businesses.High Production and Storage CostsComplex infrastructure and procedures are needed to produce and store medicinal gases, which raises supply chain costs. To guarantee purity and safety, the gases need to be produced under exacting circumstances, which calls for cutting-edge technology and strict adherence to regulations. Energy-intensive systems are needed for compression and liquefaction, and storage facilities need to be built to withstand temperature changes, pollution, and leakage.
Specialized, frequently temperature-controlled containers that adhere to stringent rules are also necessary for the transportation of these gases. Long-term costs are further increased by continuing storage system monitoring and maintenance. These elements work together to make medical gases far more expensive to produce, handle, and distribute than many other medical supplies, which puts a strain on both healthcare providers and suppliers.
Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Revenue Analysis
Air Liquide
Linde Plc
Atlas Copco Group
Inox-Air Products Inc.
Taiyo Nippon Sanso Corporation
Matheson Tri-Gas, Inc.
Horiba Group
Sol India Private Limited
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$14.41 Billion
Forecasted Market Value (USD) by 2033
$28.61 Billion
Compound Annual Growth Rate
7.9%
Regions Covered
Global
Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Medical Gas Market5.1 Historical Market Trends5.2 Market Forecast6. Medical Gas Market Share Analysis6.1 By Product6.2 By Application6.3 By End Use6.4 By Countries7. Product7.1 Pure Gases7.2 Gas Mixtures8. Application8.1 Therapeutics8.2 Diagnostics8.3 Others9. End Use9.1 Hospitals9.2 Pharmaceutical & Biotechnology Companies9.3 Ambulatory Surgical Centers9.4 Diagnostic & Research Laboratories9.5 Academic & Research Institutes9.6 Home Healthcare10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 South Korea10.3.5 Thailand10.3.6 Malaysia10.3.7 Indonesia10.3.8 Australia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 Saudi Arabia10.5.2 UAE10.5.3 South Africa11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/xazhcn
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Medical Gas Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Study attributes 440 'excess deaths' to January's Los Angeles wildfires
By Steve Gorman LOS ANGELES (Reuters) -Wildfires that devastated parts of the Los Angeles area in January indirectly led to hundreds of deaths in the ensuing weeks, far exceeding the official toll of 31 fatalities, according to a study released on Wednesday. The research, published in the Journal of the American Medical Association, or JAMA, estimated 440 "excess deaths" were attributable to the fires from January 5 to February 1, using models that compared predicted mortality under normal circumstances to actual numbers documented during that period. The additional deaths likely reflect a mix of factors, including increased exposure of people with heart and lung disease to poor air quality from smoke and toxins released by the fires, as well as healthcare delays and disruptions, the study said. The findings "underscore the need to complement direct fatalities estimates with alternative methods to quantify the additional mortality burden of wildfires and of climate-related emergencies more broadly," the researchers wrote. Two wind-driven wildfires that erupted during the first week of January on opposite sides of Los Angeles damaged or destroyed nearly 16,000 structures combined - laying waste to much of the seaside district of Pacific Palisades and the foothill community of Altadena. Together, the blazes scorched 59 square miles (152 sq km), an area larger than Paris. The official tally of people who perished as a direct result of the fires stands at 31, after the most recent set of human remains were unearthed in Altadena in July, six months after the fires. Governor Gavin Newsom in February requested nearly $40 billion in wildfire aid from Congress. Some estimates put economic losses from the fires at more than $250 billion, making the conflagration one of the most costly natural disasters in U.S. history. The JAMA study acknowledged some limitations, saying the data may need to be revised upward in the future and the research did not reflect any fire-attributable deaths beyond Feb. 1.
Yahoo
2 hours ago
- Yahoo
Cencora (COR) Reports Q3 Earnings Growth, Maintains US$0.55 Dividend
Cencora recently announced strong third-quarter earnings with sales at $80,664 million and net income rising to $687 million, reflecting significant growth. Despite these robust results, the stock price remained flat over the last quarter. These financial achievements, along with a quarterly dividend declaration of $0.55 per share, indicate Cencora's continued shareholder commitment. Although the broader market fluctuated amidst tariff news and earnings reports from other major firms, Cencora's steady performance might have balanced against market volatility, providing stability amidst economic uncertainties. We've identified 3 possible red flags for Cencora that you should be aware of. These 19 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The recent announcement of Cencora's strong third-quarter earnings reflects well on the company's long-term trajectory, especially given the reported five-year total return of 191.02%. This impressive return includes both share price appreciation and dividends, indicating a robust performance over the period. In contrast, for the past year, Cencora's return surpassed the US Healthcare industry's performance although it lagged behind the broader US market, which saw a 21.3% return over the same timeframe. This long-term performance, however, highlights the company's resilience and growth potential amid short-term market fluctuations. While the recent earnings report and consistent dividend payout suggest a commitment to shareholder value, market conditions and external economic factors have kept the stock price relatively stable in the short term. Analysts expect the company's strategic moves, such as the integration of US and European 3PL operations, to bolster its revenue and earnings forecasts. With current revenue at $316.65 billion and earnings at $1.9 billion, projections for future growth remain positive, although challenges like foreign exchange risks and interest expenses may impact profitability. At a current share price of $283.78, Cencora trades at a discount to its consensus price target of $330.07, which indicates potential upside if the company effectively capitalizes on its growth opportunities going forward. The valuation report we've compiled suggests that Cencora's current price could be inflated. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include COR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate
Explore Rhythm Biosciences's Fair Values from the Community and select yours Just because a business does not make any money, does not mean that the stock will go down. Indeed, Rhythm Biosciences (ASX:RHY) stock is up 181% in the last year, providing strong gains for shareholders. But while history lauds those rare successes, those that fail are often forgotten; who remembers Given its strong share price performance, we think it's worthwhile for Rhythm Biosciences shareholders to consider whether its cash burn is concerning. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Does Rhythm Biosciences Have A Long Cash Runway? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at December 2024, Rhythm Biosciences had cash of AU$4.5m and no debt. In the last year, its cash burn was AU$2.1m. That means it had a cash runway of about 2.1 years as of December 2024. That's decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below. Check out our latest analysis for Rhythm Biosciences How Is Rhythm Biosciences' Cash Burn Changing Over Time? In the last year, Rhythm Biosciences did book revenue of AU$3.2m, but its revenue from operations was less, at just AU$1.5m. Given how low that operating leverage is, we think it's too early to put much weight on the revenue growth, so we'll focus on how the cash burn is changing, instead. Notably, its cash burn was actually down by 75% in the last year, which is a real positive in terms of resilience, but uninspiring when it comes to investment for growth. Admittedly, we're a bit cautious of Rhythm Biosciences due to its lack of significant operating revenues. So we'd generally prefer stocks from this list of stocks that have analysts forecasting growth. How Hard Would It Be For Rhythm Biosciences To Raise More Cash For Growth? While we're comforted by the recent reduction evident from our analysis of Rhythm Biosciences' cash burn, it is still worth considering how easily the company could raise more funds, if it wanted to accelerate spending to drive growth. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Rhythm Biosciences' cash burn of AU$2.1m is about 2.8% of its AU$77m market capitalisation. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares. How Risky Is Rhythm Biosciences' Cash Burn Situation? It may already be apparent to you that we're relatively comfortable with the way Rhythm Biosciences is burning through its cash. For example, we think its cash burn reduction suggests that the company is on a good path. And even its cash runway was very encouraging. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash. Separately, we looked at different risks affecting the company and spotted 6 warning signs for Rhythm Biosciences (of which 2 are a bit concerning!) you should know about. Of course Rhythm Biosciences may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
